29 related articles for article (PubMed ID: 19830863)
1. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.
Maliakal P; Abdelrahim M; Sankpal UT; Maliakal C; Baker CH; Safe S; Herrera LJ; Abudayyeh A; Kaja S; Basha R
Invest New Drugs; 2012 Jun; 30(3):853-61. PubMed ID: 21197621
[TBL] [Abstract][Full Text] [Related]
2. [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Zhang T; Su LW; Zhu YF; Lang HJ; Zhang F; Zhou YA; Liang XH; Wang YJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 May; 15(5):512-6. PubMed ID: 22648851
[TBL] [Abstract][Full Text] [Related]
3. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Heath EI; Canto MI; Piantadosi S; Montgomery E; Weinstein WM; Herman JG; Dannenberg AJ; Yang VW; Shar AO; Hawk E; Forastiere AA;
J Natl Cancer Inst; 2007 Apr; 99(7):545-57. PubMed ID: 17405999
[TBL] [Abstract][Full Text] [Related]
4. Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Liu FX; Wang WH; Wang J; Li J; Gao PP
Helicobacter; 2011 Feb; 16(1):66-77. PubMed ID: 21241415
[TBL] [Abstract][Full Text] [Related]
5. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
[TBL] [Abstract][Full Text] [Related]
6. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
Kaur BS; Khamnehei N; Iravani M; Namburu SS; Lin O; Triadafilopoulos G
Gastroenterology; 2002 Jul; 123(1):60-7. PubMed ID: 12105834
[TBL] [Abstract][Full Text] [Related]
7. [Chemoprevention of Barrett's esophagus by celecoxib in rats].
Wang RH; Ou-Yang Q; Chen X; Li GD; Xiang JY
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):498-504. PubMed ID: 19830863
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Heath EI; Canto MI; Wu TT; Piantadosi S; Hawk E; Unalp A; Gordon G; Forastiere AA;
Dis Esophagus; 2003; 16(3):177-86. PubMed ID: 14641306
[TBL] [Abstract][Full Text] [Related]
9. [The clinical strategy for the Barrett's esophagus].
Kitabatake S; Niwa Y; Goto H
Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
Piazuelo E; Jimenez P; Lanas A
Curr Pharm Des; 2003; 9(27):2267-80. PubMed ID: 14552327
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
Bresalier RS
Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
